Since the Leber congenital amaurosis (LCA2, with RPE65 mutation) clinical trial began and only one eye was treated each time [21–24], this raises the concern that an initial subretinal injection may affect the future therapeutic effect of later treatments in the contralateral eye of that patient. This evidence concerns the gene RPE65 and Leber congenital amaurosis.